Maze Therapeutics
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Find out what a historical investment in Maze Therapeutics would be worth today using our MAZE stock calculator.
$2.04B
-
0.00%
92.09K
$42.92
$41.46
$42.33
$43.29
$6.71
Ready to start your investing journey with Stake?
Open an accountMAZE FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in MAZE
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in MAZE
on Stake
Buy MAZE from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of MAZE from only US$10 with fractional shares
